Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Alferon LDO

Recombinant protein · Immune activation · developed by AIM ImmunoTech

Phase 2 Most advanced trial (none active)

AIM Developer

1 Registered trials

What is Alferon LDO?

Alferon LDO is a recombinant interferon alpha formulation administered orally as a lozenge. It is studied in HIV infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Recombinant protein
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: AIM ImmunoTech Inc. (AIM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00215852	Phase 2	HIV Infections	Terminated	AIM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV Infections

More from AIM ImmunoTech

Rintatolimod Phase 3

Sources

ClinicalTrials.gov NCT00215852

Updated Oct 3, 2026. Something wrong or missing? Report it on the AIM page.

Follow AIM, the company behind Alferon LDO

See AIM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AIM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z